Trial Background: The Phase 1/2 clinical trial of YH32364 commenced on June 12, 2025. The trial is focused on patients with advanced solid tumors who have failed prior treatments. EGFR-overexpressing cancers often exhibit resistance to existing standard treatments, highlighting the urgent need for novel therapeutic options. ## Target Patients and Indications: The trial is recruiting adult patients aged 18 years or older with locally advanced or metastatic solid tumors that overexpress EGFR. Patients who have not responded to previous treatments are prioritized. This strategy targets a patient population with limited existing treatment options. ## Mechanism and Differentiation: YH32364 is an EGFR inhibitor designed to block signaling on the surface of tumor cells, thereby inhibiting growth and metastasis. Compared to existing EGFR-targeted drugs, YH32364 may offer improved selectivity or a more favorable safety profile. However, as it is still in Phase 1/2, its clinical efficacy and safety are still under investigation. ## Market and Investment Implications: EGFR-overexpressing cancers affect millions of people worldwide, representing a significant market opportunity. Success in this trial could strengthen Yuhan Corp's pipeline and enhance the global presence of Korean biotech companies. Conversely, failure to advance to Phase 2 would require investors to reassess the risks.